BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14612899)

  • 1. Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing.
    Iwadate Y; Fujimoto S; Namba H; Yamaura A
    Br J Cancer; 2003 Nov; 89(10):1896-900. PubMed ID: 14612899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis.
    Iwadate Y; Fujimoto S; Yamaura A
    Int J Mol Med; 2002 Aug; 10(2):187-92. PubMed ID: 12119557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme.
    Gruber ML; Glass J; Choudhri H; Nirenberg A
    Am J Clin Oncol; 1998 Aug; 21(4):338-40. PubMed ID: 9708629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
    Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
    J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.
    Silvani A; Gaviani P; Lamperti EA; Eoli M; Falcone C; Dimeco F; Milanesi IM; Erbetta A; Boiardi A; Fariselli L; Salmaggi A
    J Neurooncol; 2009 Aug; 94(1):57-62. PubMed ID: 19212704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.
    Choi IS; Lee SH; Kim TY; Bang JS; Paek SH; Kim S; Kim IH; Heo DS; Bang YJ; Kim DG; Jung HW; Kim NK
    J Neurooncol; 2002 Nov; 60(2):171-6. PubMed ID: 12635665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.
    Varveris H; Petinelli E; Stratakis J; Mazonakis M
    Oncol Rep; 2008 Feb; 19(2):447-55. PubMed ID: 18202794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
    Gross MW; Altscher R; Brandtner M; Häusser-Mischlich H; Kiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Strahlenther Onkol; 2001 Dec; 177(12):656-61. PubMed ID: 11789404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.
    Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH
    J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
    Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy.
    Madajewicz S; Chowhan N; Tfayli A; Roque C; Meek A; Davis R; Wolf W; Cabahug C; Roche P; Manzione J; Iliya A; Shady M; Hentschel P; Atkins H; Braun A
    Cancer; 2000 May; 88(10):2350-6. PubMed ID: 10820358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
    Dillman RO; Shea WM; Tai DF; Mahdavi K; Barth NM; Kharkar BR; Poor MM; Church CK; DePriest C
    Neuro Oncol; 2001 Jan; 3(1):35-41. PubMed ID: 11305415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
    Simon JM; Noël G; Chiras J; Hoang-Xuan K; Delattre JY; Baillet F; Mazeron JJ
    Radiother Oncol; 2003 Apr; 67(1):45-51. PubMed ID: 12758239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
    Vrdoljak E; Boban M; Saratlija-Novaković Z; Jović J
    Croat Med J; 2006 Apr; 47(2):305-9. PubMed ID: 16625697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.